Hepatitis B and measles seroprevalence among Turkish children

Basit Öğe Kaydı
dc.authorscopusid7004528527
dc.authorscopusid7003829656
dc.authorscopusid7003836321
dc.authorscopusid7003387214
dc.authorscopusid7003363965
dc.authorscopusid7004380255
dc.authorscopusid57997023000
dc.contributor.authorKanra G.
dc.contributor.authorTezcan S.
dc.contributor.authorBadur S.
dc.contributor.authorAlp H.
dc.contributor.authorBulut A.
dc.contributor.authorCin S.
dc.contributor.authorMocan G.
dc.date.accessioned2024-06-12T10:27:57Z
dc.date.available2024-06-12T10:27:57Z
dc.date.issued2005
dc.description.abstractThis study was performed to determine hepatitis B and measles seroprevalence among the population under 30 years of age in Turkey. Blood samples of 2,683 subjects from eight provinces of Turkey were studied. Measles IgG was determined by hemagglutinin inhibition method, and hepatitits B surface antigen (HBsAg), anti-hepatitis B surface antibody (anti-HBs) and anti-hepatitis B core antibodies (anti-HBc) were determined by ELISA method. Overall seropositivity for measles was found to be 59.6%. There was a significant difference in seropositivity among provinces. The seropositivity was found to increase with age. The overall seropositivities for HBsAg, anti-HBs and anti-HBc were found to be 5.4%, 17% and 15.1 %, respectively. The seroprevalences differed significantly among provinces. Although seroprevalence for anti-HBs and anti-HBc increased with age, HBsAg seropositivity did not change significantly after one year of age. Seroprevalence was not affected by sex. It was concluded that every effort should be given to vaccinate infants as early as possible for hepatitis B and that the coverage of infancy measles vaccination should be increased with a second dose.en_US
dc.identifier.endpage110en_US
dc.identifier.issn0041-4301
dc.identifier.issue2en_US
dc.identifier.pmid16052847en_US
dc.identifier.scopus2-s2.0-20144371839en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage105en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17013
dc.identifier.volume47en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Pediatricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatitis B; Measles; Seroprevalenceen_US
dc.subjectHepatitis B Core Antibody; Hepatitis B Surface Antibody; Hepatitis B Surface Antigen; Hepatitis B Vaccine; Immunoglobulin G; Measles Vaccine; Adolescent; Age Distribution; Aged; Article; Blood Sampling; Child; Childhood Disease; Controlled Study; Enzyme Linked Immunosorbent Assay; Female; Geographic Distribution; Hemagglutination Inhibition Test; Hepatitis B; Human; Major Clinical Study; Male; Measles; Measles Vaccination; Population Research; Serodiagnosis; Seroprevalence; Sex Difference; Turkey (Republic); Vaccination; Adolescent; Adult; Age Factors; Child; Child, Preschool; Cluster Analysis; Female; Hepatitis B; Hepatitis B Surface Antigens; Humans; Infant; Male; Measles; Seroepidemiologic Studies; Turkeyen_US
dc.titleHepatitis B and measles seroprevalence among Turkish childrenen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu